Skip to main content

Advertisement

SpringerLink
Log in

Serious adverse drug reactions with sacubitril/valsartan Entresto®: a French pharmacovigilance survey

  • Letter to the Editor
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. McMurray JJV, PackeR M, DesaI AS, Jianjian Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, For the PARADIGM-HF investigators and committees (2014) Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004

    Article  PubMed  CAS  Google Scholar 

  2. Vial T (2016) French pharmacovigilance: missions, organization and perspectives. Therapie 71:143–150

    Article  PubMed  Google Scholar 

  3. Miremont-Salamé G, Théophile H, Haramburu F, Bégaud B (2016) Causality assessment in pharmacovigilance: the French method and its successive updates. Therapie 71:179–186

    Article  PubMed  Google Scholar 

  4. European Medicine Agency. Entresto Summary of Product Characteristics. www.ema.europa.eu/docs. Accessed 13 Feb 2018

  5. Patel N, Gluck J (2017) Is Entresto good for the brain? World J Cardiol 9:594–599

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d’Informations sur le Médicament, CIC 1436, INSERM UMR 1027, Faculté de Médecine, Centre Hospitalier Universitaire, 37, allées Jules-Guesde, 31000, Toulouse, France

    Florence Moulis, Vanessa Rousseau, Leila Chebane, Geneviève Durrieu, François Montastruc & Jean-Louis Montastruc

  2. Service de Pharmacologie Médicale, Centre de PharmacoVigilance, Centre Hospitalier Universitaire, Pôle de Santé Publique, Inserm Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, University of Bordeaux, 33000, Bordeaux, France

    Amandine Gouverneur

  3. Centre de PharmacoVigilance du Nord Pas-de-Calais, CHRU, 1 place de Verdun, 59037, Lille cedex, France

    Louise Gaboriau

  4. Centre Régional de PharmacoVigilance, CHU Montpellier, 34295, Montpellier, France

    Jean-Luc Faillie

  5. Laboratoire de Biostatistique, Epidémiologie et Santé Publique, EA 2415, Université de Montpellier, Montpellier, France

    Jean-Luc Faillie

Authors
  1. Florence Moulis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vanessa Rousseau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leila Chebane
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amandine Gouverneur
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Louise Gaboriau
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jean-Luc Faillie
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Geneviève Durrieu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. François Montastruc
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jean-Louis Montastruc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Louis Montastruc.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflict of interest.

Disclaimer

The content of this article only involved the authors and the opinions and conclusions are not necessary those of ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé). Authors of this article are solely responsible for the conclusions.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moulis, F., Rousseau, V., Chebane, L. et al. Serious adverse drug reactions with sacubitril/valsartan Entresto®: a French pharmacovigilance survey. Eur J Clin Pharmacol 74, 983–984 (2018). https://doi.org/10.1007/s00228-018-2460-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-018-2460-2

Search

Navigation